Brookfield Asset Management Ltd. (BAM)vsHelius Medical Technologies Inc Class A (HSDT)
BAM
Brookfield Asset Management Ltd.
$46.70
+1.09%
FINANCIAL SERVICES · Cap: $76.25B
HSDT
Helius Medical Technologies Inc Class A
$1.48
-7.50%
FINANCIAL SERVICES · Cap: $74.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Brookfield Asset Management Ltd. generates 52815% more annual revenue ($5.07B vs $9.59M). BAM leads profitability with a 49.7% profit margin vs 0.0%. BAM earns a higher WallStSmart Score of 68/100 (B-).
BAM
Strong Buy68
out of 100
Grade: B-
HSDT
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 33 in profit
Keeps 50 of every $100 in revenue as profit
Strong operational efficiency at 64.5%
Large-cap with strong market position
Revenue surging 23.8% year-over-year
Reasonable price relative to book value
Revenue surging 7290.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.9x book value
Grey zone — moderate risk
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -137.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BAM
The strongest argument for BAM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 49.7% and operating margin at 64.5%. Revenue growth of 23.8% demonstrates continued momentum.
Bull Case : HSDT
The strongest argument for HSDT centers on Price/Book, Revenue Growth. Revenue growth of 7290.0% demonstrates continued momentum.
Bear Case : BAM
The primary concerns for BAM are P/E Ratio, Price/Book, Altman Z-Score.
Bear Case : HSDT
The primary concerns for HSDT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BAM profiles as a growth stock while HSDT is a hypergrowth play — different risk/reward profiles.
BAM carries more volatility with a beta of 1.25 — expect wider price swings.
HSDT is growing revenue faster at 7290.0% — sustainability is the question.
BAM generates stronger free cash flow (339M), providing more financial flexibility.
Bottom Line
BAM scores higher overall (68/100 vs 37/100), backed by strong 49.7% margins and 23.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brookfield Asset Management Ltd.
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets.
Visit Website →Helius Medical Technologies Inc Class A
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.
Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?